WO2004087955A8 - Marqueurs pour la roscovitine - Google Patents

Marqueurs pour la roscovitine

Info

Publication number
WO2004087955A8
WO2004087955A8 PCT/GB2004/001337 GB2004001337W WO2004087955A8 WO 2004087955 A8 WO2004087955 A8 WO 2004087955A8 GB 2004001337 W GB2004001337 W GB 2004001337W WO 2004087955 A8 WO2004087955 A8 WO 2004087955A8
Authority
WO
WIPO (PCT)
Prior art keywords
roscovitine
markers
cdkis
candidate
vitro
Prior art date
Application number
PCT/GB2004/001337
Other languages
English (en)
Other versions
WO2004087955A1 (fr
Inventor
Simon R Green
Paul Workman
Steven R Whittaker
Original Assignee
Cyclacel Ltd
Cancer Rec Tech Ltd
Simon R Green
Paul Workman
Steven R Whittaker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd, Cancer Rec Tech Ltd, Simon R Green, Paul Workman, Steven R Whittaker filed Critical Cyclacel Ltd
Priority to JP2006506039A priority Critical patent/JP2006521806A/ja
Priority to EP04723636A priority patent/EP1613770A1/fr
Priority to CA002519491A priority patent/CA2519491A1/fr
Publication of WO2004087955A1 publication Critical patent/WO2004087955A1/fr
Publication of WO2004087955A8 publication Critical patent/WO2004087955A8/fr
Priority to US11/238,251 priority patent/US20060188898A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des marqueurs pharmacodynamiques pour des inhibiteurs de kinases dépendantes des cyclines (CDKI), notamment le candidat purine 2, 6, 9-tri-substitutée connu en tant que roscovitine. L'identité de ces marqueurs facilitent l'identification de l'activité de type roscovitine à la fois in vitro et in vivo.
PCT/GB2004/001337 2003-04-02 2004-03-26 Marqueurs pour la roscovitine WO2004087955A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006506039A JP2006521806A (ja) 2003-04-02 2004-03-26 ロスコビチン用マーカー
EP04723636A EP1613770A1 (fr) 2003-04-02 2004-03-26 Marqueurs pour la roscovitine
CA002519491A CA2519491A1 (fr) 2003-04-02 2004-03-26 Marqueurs pour la roscovitine
US11/238,251 US20060188898A1 (en) 2003-04-02 2005-09-29 Markers for roscovitine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0307640.3 2003-04-02
GBGB0307640.3A GB0307640D0 (en) 2003-04-02 2003-04-02 Markers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/238,251 Continuation US20060188898A1 (en) 2003-04-02 2005-09-29 Markers for roscovitine

Publications (2)

Publication Number Publication Date
WO2004087955A1 WO2004087955A1 (fr) 2004-10-14
WO2004087955A8 true WO2004087955A8 (fr) 2004-12-16

Family

ID=9956065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001337 WO2004087955A1 (fr) 2003-04-02 2004-03-26 Marqueurs pour la roscovitine

Country Status (6)

Country Link
US (1) US20060188898A1 (fr)
EP (1) EP1613770A1 (fr)
JP (1) JP2006521806A (fr)
CA (1) CA2519491A1 (fr)
GB (1) GB0307640D0 (fr)
WO (1) WO2004087955A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012875A2 (fr) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarqueurs de modulation des kinases dependantes des cyclines
WO2007005879A2 (fr) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
GB0525900D0 (en) * 2005-12-20 2006-02-01 Cyclacel Ltd Markers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6660750B2 (en) * 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
GB0307643D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers

Also Published As

Publication number Publication date
US20060188898A1 (en) 2006-08-24
JP2006521806A (ja) 2006-09-28
GB0307640D0 (en) 2003-05-07
CA2519491A1 (fr) 2004-10-14
EP1613770A1 (fr) 2006-01-11
WO2004087955A1 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
NO20013023D0 (no) Brystkopp, samt fremgangsmåte ved fremstilling av brystkopp, samt anvendelse av denne
WO2005107491A3 (fr) Chromatographie d'affinite multi-lectine et ses utilisations
GB0221053D0 (en) Single-molecule in vitro evolution
WO2005097140A3 (fr) Antagonistes selectifs des recepteurs a2a de l'adenosine
WO2001088103A3 (fr) Compositions et procedes de dedifferenciation cellulaire et regeneration tissulaire
IT1337796B1 (it) Procedimento per il riconoscimento, l'analisi e la valutazione delle deformazioni in particolare in automezzi
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
WO2004000094A3 (fr) Marqueurs predictifs utilises dans le traitement du cancer
IL152891A0 (en) Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids
WO2005116252A8 (fr) Procede d'evaluation de sequences de ribonucleotides
WO2001062979A3 (fr) Procede permettant d'identifier des agonistes partiels du recepteur a¿2a?
HK1080074A1 (zh) 作為酪氨酸蛋白激酶抑制劑的4，6-二氨基取代-2-[氧基或氨氧基]-[1，3，5]三嗪
HUP0303034A3 (en) Novel 7-azaindole-derivatives, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU2002365365A1 (en) Metal complex compounds
WO2005089294A3 (fr) Synthese d'indenoisoquinoliniums et techniques d'utilisation
WO2004087954A3 (fr) Marqueurs
WO2004087955A8 (fr) Marqueurs pour la roscovitine
WO2002061386A3 (fr) Marqueur
EP2757197A3 (fr) Éléments et articles rétroréfléchissants
WO2007066129A3 (fr) Procede pour detecter des lesions musculo-squelettiques
WO2007066131A3 (fr) Procede pour detecter des lesions musculo-squelettiques
AU2001272909A1 (en) Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
GB9917704D0 (en) Tanning leather
AU2001265131A1 (en) Structure-based methods for assessing amino acid variances
GB0203930D0 (en) Testing of leather

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 42/2004 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

WWE Wipo information: entry into national phase

Ref document number: 2519491

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11238251

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006506039

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004723636

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004723636

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11238251

Country of ref document: US